Aradigm Corporation
http://www.aradigm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aradigm Corporation
Maze Finds A Way As Shionogi Signs On To Develop Pompe Drug
Months after an antitrust lawsuit challenged its deal with Sanofi and raised uncertainty about the future of MZE001, Maze secured a new partner for potentially the first oral Pompe disease drug.
Astellas Rejigs R&D Focus Areas As It Withdraws From Mitochondria R&D
As Astellas pivots through several candidates in an attempt to create its next blockbuster, a decision to terminate its only prospect in the core mitochondrial R&D area leaves very few other competitors in the market.
Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program
The drug maker said the program would allow for continued reimbursement when patients change insurance plans. A Sangamo-partnered gene therapy for hemophilia A is also in the works.
AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next
Outstanding Q1 growth in sales and profits have pleased the markets, and investors are now keen to hear more about AstraZeneca’s 2030 masterplan at its investor day next month.
Company Information
- Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice